Literature DB >> 1866141

Visual and refractive results of multifocal intraocular lenses.

H V Gimbel1, D R Sanders, M G Raanan.   

Abstract

One hundred forty-nine selected patients with bilateral multifocal intraocular lenses (IOLs) were evaluated and compared retrospectively with 131 patients with bilateral monofocal IOLs. Seventy-eight percent of multifocal cases and 74.8% of monofocal cases had uncorrected visual acuity of 20/40 or better. Fifty-four percent of multifocal cases had near uncorrected visions of J1 to J3. Eighteen percent had best-corrected near vision of J4 or worse. Sixty-three percent of multifocal cases versus 4% of monofocal cases needed no spectacle correction. Multifocal cases reported significantly more visual side effects (flare, glare, and halos). The 10% of cases with poor satisfaction (rating vision as fair-to-poor) had significantly (P = 0.03) more postoperative astigmatism (1.1 prism diopters [D] versus 0.74 D) compared with satisfied (good-to-excellent) cases. Patients who were dissatisfied reported more need for corrective lenses but not more side effects. A greater decrease in contrast sensitivity at low contrast levels was detected among multifocal cases. Both groups had similar contrast sensitivity at 96% and 50% contrast, but at 11% contrast, multifocal cases averaged a loss of 3.45 Snellen lines (to 20/48.2) compared with 2.65 lines (to 20/36) for monofocal cases.

Entities:  

Mesh:

Year:  1991        PMID: 1866141     DOI: 10.1016/s0161-6420(91)32205-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

Review 1.  An update on multifocal lens implants.

Authors:  P Percival
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

2.  Bilateral implantation of multifocal versus monofocal intraocular lens in children above 5 years of age.

Authors:  Jagat Ram; Aniruddha Agarwal; Jaidrath Kumar; Adit Gupta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-19       Impact factor: 3.117

3.  Objective evaluation of through-focus optical performance of presbyopia-correcting intraocular lenses using an optical bench system.

Authors:  Myoung Joon Kim; Len Zheleznyak; Scott Macrae; Hungwon Tchah; Geunyoung Yoon
Journal:  J Cataract Refract Surg       Date:  2011-07       Impact factor: 3.351

4.  Evaluation of refractive correction for standard automated perimetry in eyes wearing multifocal contact lenses.

Authors:  Kazunori Hirasawa; Hikaru Ito; Yukari Ohori; Yui Takano; Nobuyuki Shoji
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

5.  Optics of conductive keratoplasty: implications for presbyopia management.

Authors:  Peter S Hersh
Journal:  Trans Am Ophthalmol Soc       Date:  2005

6.  Tritan colour contrast sensitivity function in refractive multifocal intraocular lenses.

Authors:  S Pieh; G Hanselmayer; B Lackner; P Marvan; A Grechenig; H Weghaupt; C Vass; C Skorpik
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

Review 7.  Multifocal versus monofocal intraocular lenses after cataract extraction.

Authors:  Samantha R de Silva; Jennifer R Evans; Varo Kirthi; Mohammed Ziaei; Martin Leyland
Journal:  Cochrane Database Syst Rev       Date:  2016-12-12

8.  Comparison of outcomes with multifocal intraocular lenses: a meta-analysis.

Authors:  Béatrice Cochener; Antoine Lafuma; Babak Khoshnood; Laurène Courouve; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2011-01-07

9.  Patient-reported benefit of ReSTOR multi-focal intraocular lenses after cataract surgery: results of principal component analysis on clinical trial data.

Authors:  Gilles Berdeaux; Muriel Viala; Aude Roborel de Climens; Benoit Arnould
Journal:  Health Qual Life Outcomes       Date:  2008-01-24       Impact factor: 3.186

10.  Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countries.

Authors:  Antoine Lafuma; Gilles Berdeaux
Journal:  BMC Ophthalmol       Date:  2008-07-15       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.